Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Home

Marketplace
Database
News
Store
Resources
Contact Us

 

 

News


VENTURE CAPITAL DIRECTORY | PRIVATE EQUITY DIRECTORY

List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory

VCPro Database 2021 New Edition Special Offer!
Buy Now for $119.95 with a FREE mid-year update in July 2021
Learn More or Buy Now

VCPro Database 2021 24th Edition -- a downloadable and searchable venture capital database with 6,400+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. (Updated JANUARY 2021)

Learn More » or Buy Now »




Qiming Venture Partners Announces Final Closing of US$ 1.2 Billion Fund VII

Fund targets early stage healthcare and technology investments

SHANGHAI, November 18, 2020-- Qiming Venture Partners today announced the final closing of Qiming Venture Partners Fund VII, a $1.2 billion fund focuses on early-stage Healthcare and TMT investments. As of today, this is the largest VC fund raising in 2020 which primarily focuses on China market investments, according to public information. As in prior funds, the vast majority of Fund VII's capital comes from a prestigious group of endowments, foundations, family offices, and private pensions.

Fund VII is led by Managing Partners Duane Kuang, Nisa Leung, William Hu, and Gary Rieschel, with the full support of investment and administrative teams based in Shanghai, Beijing, Shenzhen, and Hong Kong.

Since its inception in 2006, Qiming has demonstrated its ability to deliver consistent top decile returns for the venture capital field in China. Qiming has backed over 370 fast-growing companies, over thirty of which have achieved unicorn status. A vast majority of these companies were early stage at the time of initial investment. In addition, over forty of our portfolio companies are now public, including Xiaomi, Gan & Lee Pharmaceuticals, Meituan, Bilibili, Roborock, Tigermed, Zai Lab, CanSino Biologics, Sanyou and Venus Medtech. We have more than thirty portfolio companies expecting to IPO soon.

"International investors are bullish about China's economy and optimistic about the investment return from the China market. They are keen on investing in China's top-tier VC funds," said Duane Kuang, Founding Managing Partner of Qiming Venture Partners.

Qiming Venture Partners today also announced the first closing of RMB fund VI.

Qiming continues to be an active investor in 2020, with over 60 investments completed in the TMT and Healthcare sectors. Over 80 of our portfolio companies completed new financing rounds in 2020. We expect to have the 11th successful IPO in our portfolio this year on November 20th.

"We are very grateful to our LPs for their trust and support over the last 15 years," said Nisa Leung, Managing Partner of Qiming Venture Partners. "Qiming will continue to focus on investing in visionary entrepreneurs to bring long-term value to humanity and society."

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Currently Qiming Venture Partners manages nine US Dollar funds and six RMB funds with over $5.6 billion assets under management. Since our establishment, we have invested in outstanding companies in the TMT and healthcare industries at the early and growth stages.

Since our debut, we have backed over 370 fast-growing and innovative companies. Over 120 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or achieved exit through M&A and other means. There are also over 30 portfolio companies that have achieved unicorn status.

Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), Venus MedTech (SEHK:2500), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), WeDoctor Group, and UBTech among many others.


News Index

Venture Capital Database 

 

 NEWS

Latest VC News
VC News Archive
News Search
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Business Plan Tools

Free Business Plan Template

 

Copyright © 1998-2021 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer